Medimmune Limited

Genentech, Inc.

Tanox, Inc.

Applied Molecular Evolution

Other

Astrazeneca Ab

Ixsys, Incorporated

The Feinstein Institutes for Medical Research

Herren Wu

William D Huse

Peter Kiener

James F Young

William Dall'Acqua

Leslie Sydnor Johnson

Sanjaya Singh

Anthony Coyle

Ling-Ling An

Jeffry Dean Watkins

Changshou Gao

Scott Koenig

Jeffrey D Watkins

Henry Bernard Lowman

Robert F Kelley

Sek Chung Fung

Melissa Marie Damschroder

Su-Yau Mao

Catherine Foster

Christian B Allan

Ronald Herbst

Jeffrey S Swers

Manuel Baca

Ralph Raymond Minter

Ying Tang

Partha S Chowdhury

Vahe Bedian

Julian Davies

Andrew Grier Buchanan

Michael A Bowen

Jennifer Lynne Reed

Jane Tian

Jeffrey Brown

Ricardo Cibotti

Benoy Chacko

Anthony W Siadak

Alejandro A Aruffo

Theresa O'Keefe

Shixin Qin

Jurgen Bajorath

Diane Hollenbaugh

Nazzareno Dimasi

Barbara A Thorne

Vaheh Oganesyan

Jose Casas-Finet

Linda Harris

Karen K Berry

Chris Stannard

Olga Lubman

Jose Casa-Finet

William Dall-Acqua

William Dall'acqua

Melissa Damschroder

Stabilized antibodies directed to Angiopoeitin-2 and uses of such antibodies are described. Nucleic acid and amino acid sequences, hybridomas or other cell lines for expressing such antibodies are also provided.

Stabilized angiopoietin-2 antibodies and uses thereof

The invention provides anti-IFNAR1 antibodies with reduced affinity for Fc receptors and/or ligands and methods of making and using such antibodies.

Anti-IFNAR1 antibodies with reduced Fc ligand affinity

The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.

Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease

The present invention relates to a viral vector encoding for a library of antibodies or antibody fragments that are displayed on the cell membrane when expressed in a cell. The present invention provides cells comprising the viral vector nucleic acids and methods of screening the libraries for antibodies or antibody fragments with desired characteristics.

Cell display of antibody libraries

The invention provides protein scaffolds and methods of preparing, screening, engineering and using such protein scaffolds.

Protein scaffolds

The invention relates to high affinity human monoclonal antibodies, particularly those directed against isotypic determinants of immunoglobulin E (IgE), as well as direct equivalents and derivatives of these antibodies. These antibodies bind to their respective target with an affinity at least 100 fold greater than the original parent antibody. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.

High affinity, anti-human IgE antibodies

Isolated nucleic acids encoding anti-CD19 mouse monoclonal antibodies are described herein. Also described are expression vectors, host cells and a method of producing anti-CD19 antibodies.

Humanized anti-CD19 antibodies

Provided herein are crystalline forms of a human IgG Fc variant comprising triple-mutation M252Y/S254T/T256E that provides for increased binding affinity to human neonatal Fc receptor, methods of obtaining such crystals and high-resolution X-ray diffraction structures and atomic structure coordinates. Also provided are machine readable media embedded with the three-dimensional atomic structure coordinates of the human IgG Fc variant and methods of using them.

Crystals and structure of a human IgG Fc variant with enhanced FcRn binding

The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.

Methods of detecting factor D with anti-factor D antibodies

The present invention relates to novel molecules (Fc variants) comprising at least one antigen binding region and an Fc region that further comprises a modified hinge which alters the binding of Fc to one or more Fc ligand (e.g., Fc&#x3b3;Rs) and/or modulates effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc&#x3b3;R and/or C1q. Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variants particularly for therapeutic purposes.

Modulation of antibody effector function by hinge domain engineering

The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.

Recombinant IL-9 antibodies and uses thereof

Growing community of inventors

Boyds, MD, United States of America

Herren Wu